Return to homepagePandemic Pact

Sinergium Biotech - Disease X

  • Funded by Coalition for Epidemic Preparedness Innovations (CEPI)
  • Total publications:0 publications

Grant number: CEPI-1658

Grant search

Key facts

  • Disease

    Influenza caused by Influenza A virus subtype H5, Disease X

  • Start & end year

    2025

  • Known Financial Commitments (USD)

    $1,000,000

  • Funder

    Coalition for Epidemic Preparedness Innovations (CEPI)

  • Principal Investigator

    N/A

  • Research Location

    99

  • Lead Research Institution

    Sinergium

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Vaccine design and administration

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Scientists at Argentina’s pharmaceutical company Sinergium Biotech will start preclinical testing of an innovative mRNA vaccine technology that could significantly strengthen regional pandemic preparedness and contain escalating disease outbreaks in their tracks. Backed by a US $1 million investment from CEPI, the exploratory project is among the first mRNA vaccine technologies to be assessed on the continent. The research will evaluate Sinergium’s mRNA platform—supported by the World Health Organization (WHO) and Medicines Patent Pool’s mRNA Technology Transfer Programme, and by the Pan American Health Organization (PAHO)—in preclinical studies using H5N1 avian flu as a prototype pathogen. Designed as a flexible, ‘plug-and-play’ platform, the mRNA technology, if successful, also aims to target other emerging viruses beyond H5N1 that pose threats to the region.